Viking Global Investors
Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.
Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.
View Older Stories View More Recent Stories
-
Pearl Health Partners with Story Health to Provide Scalable Specialty Cardiac Care to Medicare Beneficiaries
-
Ecovative Raises Over $30 Million, Funding Global Distribution of Planet-Friendly Fashion and Food
-
Form SC 13G Verastem, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
The Future Is Bright -- Lightmatter Raises $154M to Deliver Photonic Products to Customers
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Ensoma Closes Series B Extension, Bringing Total Round to $135 Million
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Mar 31
-
Kavitha Dasu Named Battelle Inventor of the Year
-
Form 4 4D Molecular Therapeutic For: May 09 Filed by: Viking Global Opportunities GP LLC
-
Pearl Health releases Top 50 Value-Based Care Thinkers of 2023
-
Solarea Bio Announces First Close of Series B Financing Round
-
Revive Environmental’s PFAS Annihilator™ Technology Recognized With Two Honors from Fast Company 2023 World Changing Ideas Awards
-
Revive Environmental PFAS Annihilator™ Deployed in First-to-Market Commercial Destruction of “Forever Chemicals”
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
GPS Rebrands as “Thredd” to Reflect Its Unique Position as the Go to Payments Partner of Innovators Worldwide
-
Abdera Therapeutics Debuts With $142 Million in Financing to Engineer and Advance Best-in-Class Antibody-Based Radiopharmaceuticals for Cancer
-
Mythic Therapeutics Presents Preclinical Data on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Association for Cancer Research (AACR) Annual Meeting
-
AlphaSense valued at $1.8 billion after CapitalG-backed fundraise
-
ID.me Appoints Samantha Greenberg as Chief Financial Officer and Raises $132 Million in Series D Funding
-
AlphaSense Raises $100M Led By Alphabet's CapitalG to Fuel Innovation in AI and Market Intelligence
-
Mythic Therapeutics Announces First Subject Dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
-
IGM Financial, a Member of the Power Corporation Group of Companies, Making Long-Term Strategic Investment in Rockefeller Capital Management; Becomes Shareholder Alongside Majority Investor Viking Glo
-
Cazoo Announces Fourth Quarter and Full Year 2022 Financial Results
-
Pragma Bio Secures $10M From The Venture Collective, Merck Global Health Innovation Fund, Viking Global, and CJ Investments To Expand Its Proprietary Technology Platform To Discover Novel Medicines
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Cazoo to Announce Full-Year and Fourth Quarter 2022 Results on March 30, 2023
-
CNM LLP Appoints Bill Strong as President to Lead Global Business Operations and Strategic Growth
-
Cazoo (CZOO) Provides Year-to-Date Business Performance Update
-
Cazoo Provides Year-to-Date Business Performance Update
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Equities
-
Form SC 13D/A Cazoo Group Ltd Filed by: VIKING GLOBAL INVESTORS LP
-
Cazoo (CZOO) Sells Cazana Data Platform
-
Cazoo Sells Cazana Data Platform
-
Cazoo (CZOO) Agrees Sale of German Subscription Business
-
Cazoo Agrees Sale of German Subscription Business
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Dec 31
-
Form SC 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A FIGS, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Inhibrx, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Amylyx Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Guardant Health, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Pharvaris N.V. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A PROCEPT BioRobotics Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Orion Acquisition Corp. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Edgewise Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Coupa Software Inc Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A PepGen Inc. Filed by: VIKING GLOBAL INVESTORS LP